SCHEMBL5649558

SCHEMBL5649558

O=C(Nc1ccc(O)nc1)c1ccc(Cl)cc1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 7/20 0.74
KCNQ2 O43526 7/20 0.74
KCNE1 P15382 5/20 0.74
KCNQ1 P51787 5/20 0.74
P4HTM Q9NXG6 2/20 0.68
NAMPT P43490 1/20 0.60
CYP11B1 P15538 1/20 0.59
CYP11B2 P19099 1/20 0.59
BACE1 P56817 1/20 0.59
KMT2A Q03164 2/20 0.57
NT5E P21589 1/20 0.57
MAPK1 P28482 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
RAB9A P51151 2/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 1/20 0.56
HTT P42858 1/20 0.56
NPC1 O15118 1/20 0.54
DEGS1 O15121 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20284429 0.95 KCNQ3 (0.68) KCNQ3KCNQ2KCNE1KCNQ1P4HTM
SCHEMBL5647238 0.85 KCNQ3 (0.69) KCNQ3KCNQ2KCNE1KCNQ1P4HTM
SCHEMBL5217440 0.85 KCNQ3 (1.00) KCNQ3KCNQ2KCNE1KCNQ1P4HTM
SCHEMBL5650378 0.84 KCNQ3 (0.70) KCNQ3KCNQ2KCNE1KCNQ1BACE1
SCHEMBL5648744 0.83 KCNQ3 (0.69) KCNQ3KCNQ2P4HTMNAMPTKMT2A
SCHEMBL14516646 0.81 KCNQ3 (0.71) KCNQ3KCNQ2KCNE1KCNQ1P4HTM
SCHEMBL5645475 0.81 KCNQ3 (0.72) KCNQ3KCNQ2KCNE1KCNQ1KMT2A
SCHEMBL28598761 0.81 P4HTM (1.00) KCNQ3KCNQ2KCNE1KCNQ1P4HTM
SCHEMBL10939703 0.80 NPC1 (0.76) KCNQ3KCNQ2KCNE1KCNQ1P4HTM
SCHEMBL9767723 0.80 NPC1 (0.76) KCNQ3KCNQ2KCNE1KCNQ1P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL KCNQ3 4724/4885KCNQ2 4759/4885KCNE1 4754/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL KCNQ3 4500/4885KCNQ2 4591/4885KCNE1 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.